Cipla gets approval for generic pamidronate disodium

The FDA has given approval to Cipla to sell generic pamidronate disodium, a drug used to treat high blood calcium levels caused by cancer, protecting from bone problems caused by cancer and Paget’s disease of the bone. The drug was sold under the brand Aredia belonging to Novartis but is now off patent. Cipla has got approvals for the 30mg, 60mg and 90mg injection dosages of this drug. There are many generic players in the market; in early November Strides Akorn LLC (a joint venture between Akorn and Strides Arcolabs) too had got FDA approval for this drug. Its release had cited a market of $21mn for the drug. That is a relatively small market for the companies to divide among themselves. Cipla’s share price on Friday, Nov 28 jumped 3.35% to Rs 200, and is up 9% from its level a week ago.

Comments are closed.